Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973160 | 0.92 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL4974582 | 0.86 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL6430251 | 0.84 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL4917054 | 0.84 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4978339 | 0.84 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL27618889 | 0.83 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL4908457 | 0.83 | TRPV1 (0.84) | TRPV1 | |
| SCHEMBL4972342 | 0.83 | TRPV1 (0.73) | TRPV1 | |
| Hydrochloric Acid SCHEMBL4914803 | 0.83 | TRPV1 (0.82) | TRPV1 | |
| Ngd-8243 SCHEMBL2730820 | 0.83 | TRPV1 (1.00) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | claimed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | claimed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | US | disclosed |
| US-7074799-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | TRPV1 244/4885ABCG2 300/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | TRPV1 36/4885ABCG2 654/4885 |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 244/4885ABCG2 300/4885 |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 240/4885ABCG2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.